Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laborato...

Descripción completa

Detalles Bibliográficos
Autores principales: Bubendorf, Lukas, Büttner, Reinhard, Al-Dayel, Fouad, Dietel, Manfred, Elmberger, Göran, Kerr, Keith, López-Ríos, Fernando, Marchetti, Antonio, Öz, Büge, Pauwels, Patrick, Penault-Llorca, Frédérique, Rossi, Giulio, Ryška, Aleš, Thunnissen, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Review and Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/
https://www.ncbi.nlm.nih.gov/pubmed/27535289
http://dx.doi.org/10.1007/s00428-016-2000-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/
https://www.ncbi.nlm.nih.gov/pubmed/27535289
http://dx.doi.org/10.1007/s00428-016-2000-3

Ejemplares similares